Head of Department and Professor of Leukaemia Stem Cell Biology
Brian Huntly is a clinical research scientist who combines running a laboratory group at the University of Cambridge with his practice as a consultant haematologist at Cambridge University Hospitals. As well as Head of the Department of Haematology at the University of Cambridge, he is a member of the European Hematology Association Executive Board and Chair of their Research Committee. He studied Medicine at Edinburgh, trained in Haematology in Dundee and Cambridge and is a member of the Royal College of Physicians and a Fellow of the Royal College of Pathologists. He studied for his PhD in Cambridge and performed post-doctoral work at Harvard, prior to winning the EHA-José Carreras Young Investigator Award and returning to Cambridge to set up his own research group. His lab is interested in understanding how normal stem and progenitor cell function is subverted during the step-wise evolution of acute myeloid leukaemia and other haematological malignancies. They focus particularly on transcriptional and epigenetic alterations and combine functional, genomic and proteomic techniques in mouse and cell line models, as well as human primary tumour tissue, to identify disease mechanisms and potential therapeutic targets. Amongst other recognitions for his research, he has been elected to Fellowship of the Academy of Medical Sciences. Notable achievements include:
- The first demonstration that chronic and acute myeloid leukaemia may arise in separate stem and progenitor cells (Huntly et al, Cancer Cell 2004)
- the discovery (with Tony Kouzarides) of an essential role for BET transcriptional regulators in AML and showed that BET inhibitors provide a novel therapeutic approach (Dawson et al, Nature 2011)
- the discovery that malignant lymphomas may initiate in stem and progenitor cells prior to lymphoid commitment (Horton et al, Nature Cell Biology 2017)
- establishing (with George Vassiliou) that tumour suppression by UTX/KDM6a is mediated by enhancer and chromatin remodelling but that it does not require catalytic activity (Gozdecka et al, Nature Genetics 2018)
Recent research includes:
- the most comprehensive study to assess the role of chromatin factors in normal and malignant haematopoiesis (Lara-Astiaso et al, Nat Genet, 2023)
- the first study to experimentally dissect the synergistic mechanisms between commonly occurring mutations in a haematological malignancy (Yun et al, Nat Genet, 2021)
- the first description of the endogenous HOXA9 interactome, the HOXA9-SAFB-NuRD-CBX3 complex and its importance for transcriptional repression in acute myeloid leukaemia (Agrawal-Singh et al, Blood, 2023)
Publications
George BM, Eleftheriou M, Yankova E, Perr J, Chai P, Nestola G, Almahayni K, Evans S, Damaskou A, Hemberger H, Lebedenko CG, Rak J, Yu Q, Bapcum E, Russell J, Bagri J, Volk RF, Spiekermann M, Stone RM, Giotopoulos G, Huntly BJP, Baxter J, Camargo F, Liu J, Zaro BW, Vassiliou GS, Möckl L, de la Rosa J, Flynn RA, Tzelepis K. Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein. Nat Biotechnol. 2025 Apr 23.
Gozdecka M, Dudek M, Wen S, Gu M, Stopforth RJ, Rak J, Damaskou A, Grice GL, McLoughlin MA, Bond L, Wilson R, Giotopoulos G, Mahalingam Shanmugiah V, Bakar RB, Yankova E, Cooper JL, Narayan N, Horton SJ, Asby R, Pask DC, Mupo A, Duddy G, Marando L, Georgomanolis T, Carter P, Ramesh AP, Dunn WG, Barcena C, Gallipoli P, Yusa K, Petrovski S, Wright P, Quiros PM, Frezza C, Nathan JA, Kaser A, Kar S, Tzelepis K, Mitchell J, Fabre MA, Huntly BJP*, Vassiliou GS*. Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis. Nature. 2025 Apr 16. Joint senior authors.
Kamizela AE, Leongamornlert D, Williams N, Wang X, Nyamondo K, Dawson K, Spencer Chapman M, Guo J, Lee J, Mane K, Milne K, Green AR, Chevassut T, Campbell PJ, Ellinor PT, Huntly BJP, Baxter EJ, Nangalia J.Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature. 2025 Apr;640(8060):982-990.
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Tarkar A, Schubert B, Yun H, Horton SJ, Agrawal-Singh S Dr, Hähnel PS, Basheer F, Lugo D, Eleftheriadou I, Barbash O, Dhar A, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh PS, Dawson MA, Prinjha RK, Huntly BJP, Sasca D. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation. Blood. 2025 Feb 13.
Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologica. 2024 Nov 7.
Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, Copland M, Horne G, Raghavan M, Arnold C, Collins A, Cranfield T, Cunningham N, Danga A, Forsyth P, Frewin R, Garland P, Hannah G, Avenoso D, Hassan S, Huntly BJP, Husain J, Makkuni S, Rothwell K, Khorashad J, Apperley JF, Milojkovic D. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia. 2024 Nov.
Minciacchi VR, Karantanou C, Bravo J, Pereira RS, Zanetti C, Krack T, Kumar R, Bankov K, Hartmann S, Huntly BJP, Meduri E, Ruf W, Krause DS. Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression. Blood Adv. 2024 Oct 8;8(19):4983-4996.
Chen HC, Mueller N, Stott K, Kapeni C, Rivers E, Sauer CM, Beke F, Walsh SJ, Ashman N, O'Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjoedt MO, Skjødt K, de la Roche M, de la Roche M. Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Mol Med. 2024 Sep;16(9):2233-2261.
Hernández-Sánchez A, González T, Sobas M, Sträng E, Castellani G, Abáigar M, Valk PJM, Villaverde Ramiro Á, Benner A, Metzeler KH, Azibeiro R, Tettero JM, Martínez-López J, Pratcorona M, Martínez Elicegui J, Mills KI, Thiede C, Sanz G, Döhner K, Heuser M, Haferlach T, Turki AT, Reinhardt D, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly B, Ossenkoppele G, Döhner H, Bullinger L. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 2024 Sep;38(9):1929-1937.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes AF, Gale RE, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK, Wilhelm-Benartzi CS, Huntly BJ, Russell NH, Dillon RJ. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood. 2024 Aug 15;144(7):714-728.
Beinortas T, Huntly BJP. Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia. Cell Rep Med. 2024 May 21;5(5):101565.
Macintyre E, Döhner K, Grønbæk K, Dreyling M, Huntly B, Almeida A, Gribben J; EHA Board. Precision hematology: Navigating the evolution of diagnostic classifications in the era of globalized medicine. Hemasphere. 2024 Apr 4;8(4):e65.
Agrawal-Singh S, Bagri J, Sakakini N, Huntly BJP. A guide to epigenetics in leukaemia stem cells. Mol Oncol. 2023 Dec;17(12):2493-2506.
Pereira RS, Kumar R, Cais A, Paulini L, Kahler A, Bravo J, Minciacchi VR, Krack T, Kowarz E, Zanetti C, Godavarthy PS, Hoeller F, Llavona P, Stark T, Tascher G, Nowak D, Meduri E, Huntly BJP, Münch C, Pampaloni F, Marschalek R, Krause DS. Distinct and targetable role of calcium-sensing receptor in leukaemia. Nat Commun. 2023 Oct 6;14(1):6242.
Lara-Astiaso D, Goñi-Salaverri A, Mendieta-Esteban J, Narayan N, Del Valle C, Gross T, Giotopoulos G, Beinortas T, Navarro-Alonso M, Aguado-Alvaro LP, Zazpe J, Marchese F, Torrea N, Calvo IA, Lopez CK, Alignani D, Lopez A, Saez B, Taylor-King JP, Prosper F, Fortelny N, Huntly BJP. In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis. Nat Genet. 2023 Sep;55(9):1542-1554.
Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. Ann Oncol. 2023 Sep;34(9):734-771.
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS, Asby R, van de Lagemaat LN, Mapperley C, James SC, Prehn JHM, Tzelepis K, Rouault-Pierre K, Vassiliou GS, Kranc KR, Helgason GV, Huntly BJP, Gallipoli P. Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nat Commun. 2023 Apr 14;14(1):2132.
Agrawal-Singh S, Bagri J, Giotopoulos G, Azazi DMA, Horton SJ, Lopez CK, Anand S, Bach AS, Stedham F, Antrobus R, Houghton JW, Vassiliou GS, Sasca D, Yun H, Whetton AD, Huntly BJP. HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia. Blood. 2022 Dec 28:blood.2022016528.
Meduri E, Breeze C, Marando L, Richardson SE, Huntly BJP. The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome. iScience. 2022 Nov 17;25(12):105622.
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass J, Kamdar M, Mateos Manteca MV, Tovar N, Yeh P, García Delgado R, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clin Cancer Res. 2022 Nov 9:CCR-22-1284.
Yun H, Vohra S, Lara-Astiaso D, Huntly BJP. Multiomics data integration to reveal chromatin remodeling and reorganization induced by gene mutational synergy. STAR Protoc. 2022 Oct 13;3(4):101770.
Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, Dillon R, Levine MF, Leongamornlert D, Butler A, Ganser A, Bullinger L, Döhner K, Ottmann O, Adams R, Döhner H, Campbell PJ, Burnett AK, Dennis M, Russell NH, Devlin SM, Huntly BJP*, Papaemmanuil E*. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Commun. 2022 Aug 8;13(1):4622. * Joint senior authors
Gupta S, Dovey OM, Domingues AF, Cyran OW, Cash CM, Giotopoulos G, Rak J, Cooper J, Gozdecka M, Dijkhuis L, Asby RJ, Al-Jabery N, Hernandez-Hernandez V, Prabakaran S, Huntly BJ, Vassiliou GS, Pina C. Transcriptional variability accelerates preleukemia by cell diversification and perturbation of protein synthesis. Sci Adv. 2022 Aug 5;8(31):eabn4886.
Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, Joudinaud R, Chat L, Wu HC, Duchmann M, Sodaro G, Chauvel C, Castelli FA, Vasseur L, Pacchiardi K, Belloucif Y, Laiguillon MC, Meduri E, Vaganay C, Alexe G, Berrou J, Benaksas C, Forget A, Braun T, Gardin C, Raffoux E, Clappier E, Adès L, de Thé H, Fenaille F, Huntly BJ, Stegmaier K, Dombret H, Fenouille N, Lobry C, Puissant A, Itzykson R. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia. 2022 Apr 26.
Narayan N, Huntly BJP. Targeting AML at the intersection of epigenetics and signaling. Sci Signal. 2022 Apr 19;15(730):eabo0059.
Anderson GSF, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, So T, Bloxham D, Aubareda A, Asby R, Walker I, Jenkinson L, Soilleux EJ, Roy JP, Teodosio A, Ficken CL, Officer-Jones L, Nasser S, Skerget S, Keats J, Greaves P, Tai YT, Anderson KC, MacFarlane M, Thaventhiran JE, Huntly BJP, Lehner PJ, Chapman MA. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022 Feb 8:blood.2021015161.
Arede L, Foerner E, Wind SS, Kulkarni R, Domingues AF, Giotopoulos G, Kleinwächter S, Mollenhauer-Starkl M, Davison H, Chandru A, Asby R, Samarista R, Gupta S, Forte D, Curti A, Scheer E, Huntly BJP, Tora L, Pina C. KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia. Blood Adv. 2021 Oct 15:bloodadvances.2020002842.
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS, Huntly BJP. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Nat Genet. 2021 Oct;53(10):1443-1455.
Lara-Astiaso, Huntly BJP. Protein condensates provide a platform for controlling chromatin. Nature. 2021 Sep 15;597, 642-644.
Richardson SE, Huntly BJP. Targeting Chromatin Regulation in Acute Myeloid Leukemia. Hemasphere. 2021 Jun 1;5(6):e589. doi: 10.1097/HS9.0000000000000589.
Cao H, Neerincx A, de Bono B, Lakner U, Huntington C, Elvin J, Gudgin E, Pridans C, Vickers MA, Huntly B, Trowsdale J, Barrow AD. Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells. Br J Haematol. 2021 Jun;193(5):946-950. doi: 10.1111/bjh.17496.
Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S, Huntly B, Clark RE, Thomas IF, Kjeldsen L, McMullin MF, Drummond M, Kell J, Spearing R. J Clin Oncol. Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. J Clin Oncol. 2021 Mar 10;39(8):890-901. doi: 10.1200/JCO.20.01170.
BETs Need Greens: Folate Deficiency and Resistance to MYC-Targeted Therapies. Cancer Discov. 2020 Dec;10(12):1791-1793. doi: 10.1158/2159-8290.CD-20-1333.
Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development. Nat Immunol. 2020 Nov;21(11):1408-1420. doi: 10.1038/s41590-020-0772-8.
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metab. 2020 Sep 16:S1550-4131(20)30479-4. doi: 10.1016/j.cmet.2020.09.001.
Au YZ, Gu M, De Braekeleer E, Gozdecka M, Aspris D, Tarumoto Y, Cooper J, Yu J, Ong SH, Chen X, Tzelepis K, Huntly BJP, Vassiliou G, Yusa K. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia. 2020 Aug 6. doi: 10.1038/s41375-020-1001-z.
Giotopoulos G, Huntly BJP. CML: new tools to answer old questions. Blood. 2020 Jun 25;135(26):2327-2328. doi: 10.1182/blood.2020005599.
Marando L, Huntly BJP. Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. Curr Oncol Rep. 2020 Jun 1;22(6):61. doi: 10.1007/s11912-020-00918-7.
Lang KM, Harrison KL, Williamson PR, Huntly BJP, Ossenkoppele G, Geissler J, Bereczky T, Hernández-Rivas JM, Chevrou-Séverac H, Goodbody R, Schulze-Rath R, Bullinger L. Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. Trials. 2020 May 27;21(1):437. doi: 10.1186/s13063-020-04384-1.
Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, Drummond M, Huntly B, Marshall S, McMullin MF, Neelakantan P, Raghavan M, Sivakumaran M, Tighe J, Wandroo F, Willis F, Glen F, Fildes L, Collington SJ, Ryan J, Clark RE, Mead AJ. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol. 2020 May 24. doi: 10.1111/bjh.16733.
Basilico S, Wang X, Kennedy A, Tzelepis K, Giotopoulos G, Kinston SJ, Quiros PM, Wong K, Adams DJ, Carnevalli LS, Huntly BJP, Vassiliou GS, Calero-Nieto FJ, Göttgens B. Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML. Nat Commun. 2020 Mar 16;11(1):1407. doi: 10.1038/s41467-020-15220-0.
Domingues AF, Kulkarni R, Giotopoulos G, Gupta S, Vinnenberg L, Arede L, Foerner E, Khalili M, Adao RR, Johns A, Tan S, Zeka K, Huntly BJ, Prabakaran S, Pina C. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells. Elife. 2020 Jan 27;9. pii: e51754. doi: 10.7554/eLife.51754.
Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M M.D, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020 Jan;5(1). pii: e000611. doi: 10.1136/esmoopen-2019-000611.
Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, Ghetti M, Stengel A, Guadagnuolo V, De Tommaso R, Papayannidis C, Robustelli V, Franchini E, Rorà AGLD, Ferrari A, Fontana MC, Bruno S, Ottaviani E, Soverini S, Storlazzi CT, Haferlach C, Sabattini E, Testoni N, Iacobucci I, Huntly BJP, Ficarra E, Martinelli G. Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. Cancers (Basel). 2019 Dec 5;11(12). pii: E1951. doi: 10.3390/cancers11121951.
Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, Cooke SL, Fenner R, Usheva Z, Runge HFP, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou GS, Huntly BJP, Mupo A, Bashford-Rogers RJM, Hodson DJ. Genetic modification of primary human B cells to model high-grade lymphoma. Nat Commun. 2019 Oct 4;10(1):4543. doi: 10.1038/s41467-019-12494-x.
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P, Huntly BJP. Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. Blood. 2019 Dec 12;134(24):2195-2208. doi: 10.1182/blood.2019001553.
Horton S, Huntly BJP. Kinase Networks Regulate Metabolism: I’D(H1) Never Have Guessed! Cancer Discov. 2019 Jun;9(6):699-701. doi: 10.1158/2159-8290.CD-19-0373.
Lu Y, Stuart JH, Talbot-Cooper C, Agrawal-Singh S, Huntly B, Smid AI, Snowden JS, Dupont L, Smith GL. Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6. Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11997-12006. doi: 10.1073/pnas.1816399116.
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J Exp Med. 2019 Apr 1;216(4):966-981. doi: 10.1084/jem.20181276.
Gallipoli P, Huntly BJP. Histone modifiers are oxygen sensors. Science. 2019 Mar 15;363(6432):1148-1149. doi: 10.1126/science.aaw8373.
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.
Gallipoli P, Huntly BJP. Prognostic Models Turn the Heat(IT)up on FLT3ITD -Mutated AML. Clin Cancer Res. 2019 Jan 15;25(2):460-462. doi: 10.1158/1078-0432.CCR-18-3146.
Giotopoulos G, Huntly BJP.Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML. Cancer Cell. 2018 Oct 8;34(4):533-535. doi: 10.1016/j.ccell.2018.09.004.
Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I, Anderson E, O’Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ. Population dynamics of normal human blood inferred from somatic mutations. Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0.
Marando L, Huntly BJP. Hematopoietic stem cells made BETter by inhibition. Haematologica. 2018 Jun;103(6):919-921. doi: 10.3324/haematol.2018.193706.
Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z.
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP. Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018 Apr 12;131(15):1639-1653. doi: 10.1182/blood-2017-12-820035.
Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ. Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.
Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597.
Gallipoli P, Huntly BJP. Novel epigenetic therapies in hematological malignancies: Current status and beyond. Semin Cancer Biol. 2017 Aug 4. pii: S1044-579X(17)30135-9. doi: 10.1016/j.semcancer.2017.07.005.
Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D’Andrea RJ, Wong JWH, Pimanda JE. A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.210.
Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia. 2016 Dec 2. doi: 10.1038/leu.2016.280.
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJ, Iorio F, Pina C, Vassiliou GS, Yusa K. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.
Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016 Aug 31;537(7621):544-547. doi: 10.1038/nature19353.
Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SE, Huntly BJ, Ottersbach K. Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. Cell Rep. 2016 Jul 6. pii: S2211-1247(16)30800-2. doi: 10.1016/j.celrep.2016.06.046.
Sasca D, Huntly BJ. Independence of epigenetic and genetic diversity in AML. Nat Med. 2016 Jul 7;22(7):708-9. doi: 10.1038/nm.4136.
Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016 Jun 13. doi: 10.1038/nsmb.3249.
McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood. 2016 Apr 27. pii: blood-2015-11-683334.
Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496.
Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888.
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661.
van der Weyden L, Giotopoulos G, Wong K, Rust AG, Robles-Espinoza CD, Osaki H, Huntly BJ, Adams DJ. Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia. BMC Cancer. 2015 Aug 13;15:585. doi: 10.1186/s12885-015-1586-1.
Basheer F, Huntly BJ. BET bromodomain inhibitors in leukemia. Exp Hematol. 2015 Aug;43(8):718-31. doi: 10.1016/j.exphem.2015.06.004.
Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene. 2015 Apr 20. doi: 10.1038/onc.2015.92.
Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014 Feb;28(2):311-20. doi: 10.1038/leu.2013.338.
Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA, Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia. 2014 Jan;28(1):88-97. doi: 10.1038/leu.2013.234.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391-405. doi: 10.1056/NEJMoa1312542.
Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B. HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias. Oncogene. 2013 Nov 28;32(48):5471-80. doi: 10.1038/onc.2013.175.
Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P. Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113.
Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117.
Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood. 2013 Mar 21;121(12):2289-300. doi: 10.1182/blood-2012-07-446120.
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368.
Grimwade L, Gudgin E, Bloxham D, Bottley G, Vassiliou G, Huntly B, Scott MA, Erber WN. Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. Cytometry A. 2012 Oct;81(10):896-900. doi: 10.1002/cyto.a.22116.
Anand S, Huntly BJ. Disordered signaling in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct;26(5):1017-35. doi: 10.1016/j.hoc.2012.07.004.
Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012 Aug 16;367(7):647-57. doi: 10.1056/NEJMra1112635.
Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica. 2012 Jul;97(7):966-74. doi: 10.3324/haematol.2011.054734.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ*, Kouzarides T*. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 478(7370):529-33.
*joint senior authors
Chan WI, Dawson MA, Hannah R, Paul D, Pridans C, Joshi A, Gottgens B, Van Deursen J, Huntly BJP. The transcriptional coactivator Cbp controls hematopoietic stem cell quiescence and multipotential differentiation. Mol Cell Biol. 2011 Dec;31(24):5046-60. Epub 2011 Oct 17.
Anand S, Stedham FE, Beer PA, Gudgin E, Bench AJ, Green AR, Huntly BJP. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood. 2011 Aug 11;118(6):1610-21. Epub 2011 Jun 8.
van der Weyden L, Giotopolous G, Rust AG, Matheson L, van Delft F, Kong J, Corcoran A, Huntly BJ*, Adams DJ*. Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. Blood. 2011; 118(4):1041-51. Epub 2011 May 31.
*joint senior authors
Anand S, Stedham FE, Gudgin E, Beer PA, Bench AJ, Erber W, Green AR, Huntly BJP. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood. 2011; 118(1):177-81. Epub 2011 May 11.
Kvinlaug BT, Chan WI, Bullinger L, Sears C, Paul D, Okabe R, Lee BH, Benner A, De Silva I, Valk P, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly BJP. Common and overlapping pathways contribute to the evolution of acute myeloid leukaemias. Cancer Res. 2011; 71(12):4117-29. Epub 2011 Apr 19.
Li P, Burke S, Chen X, Ortiz M, Lee S-C, Lu D, Campos L, Dougan G, Huntly BJP, Gottgens B, Jenkins N, Copeland NC, Colucci F, Liu P. Reprogramming of T Cells to Natural Killer-like Cells upon Bcl11b Deletion. Science. 2010 Jul 2; 329(5987):85-9.
Vezzoli A, Bonadies N, Allen MD, Freund SM, Santiveri CM, Kvinlaug BT, Huntly BJ, Göttgens B, Bycroft M. Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1. Nat Struct Mol Biol. 2010 May;17(5):617-9.
Zhao R, Follows GA, Beer PA, Huntly BJP, Green AR, Alexander DR. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders N Engl J Med. 2008; 359(26): 2778-89.
Scholl C, Bansal D, Döhner K, Eiwen K, Huntly BJP, Lee BH, Rücker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest. 2007 Apr 2;117(4):1037-1048.
Tothova Z, Kollipara R, Huntly BJ, Lee BH, Catrillion D, Passegue E, Cullen D, McDowell E, Lazo-Kallanian S, Williams I, DePinho R, Gilliland DG. FoxO are critical mediators of stem cell resistance to physiologic oxidative stress Cell. 2007 Jan 26;128(2):325-39.
Lee B H, Tothova Z, Levine RL, Anderson K, Cullen DE, McDowell EP, Adelsperger J, Huntly BJP, Beran M, Jacobsen SE, Gilliland DG. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12: 367-80.
Bansal D, Scholl C, Frohling S, McDowell E, Lee BH, Dohner K, Ernst P, Davidson A, Daley GQ, Zon LI, Gilliland DG, Huntly BJP. Cdx4 upregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci U S A. 2006; 103:16924-9.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsberger J, Koo S, Lee J, Gabriel S, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WJ, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia and Myeloid Metaplasia with Myelofibrosis. Cancer Cell. 2005; 7: 387-397.
Huntly BJP, Shigematzu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. MOZ-TIF2, but not BCR-ABL, confers properties of leukaemic stem cells to committed murine haematopoietic progenitors. Cancer Cell. 2004; 6: 586-595.
